Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zamboni

Showing results (71-80 of 180) with videos related to

Pageof 18
Sort By:
Cancer Chemotherapy and Pharmacology|May 19, 2011
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patientsNinh M La-Beck, Beth A Zamboni, Alberto Gabizon, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 6, 2007
Effect of moderate aerobic exercise on sympatho-vagal balance in Type 2 diabetic patientsG Zoppini, V Cacciatori, M L Gemma, et al.
Annals of the New York Academy of Sciences|December 13, 1996
Schedule-dependent efficacy of camptothecins in models of human cancerP J Houghton, C F Stewart, W C Zamboni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastomaW C Zamboni, A J Gajjar, R L Heideman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group StudyR L Saylors, C F Stewart, W C Zamboni, et al.
Pharmacotherapy|October 18, 2000
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascitesB J Delauter, R K Ramanathan, M J Egorin, et al.
Antibodies (Basel, Switzerland)|September 24, 2019
Factors Affecting the Pharmacology of Antibody-Drug ConjugatesAndrew T Lucas, Lauren S L Price, Allison N Schorzman, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|August 9, 2019
Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2Christina L Parker, Morgan D McSweeney, Andrew T Lucas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluidW C Zamboni, D I Lüftner, M J Egorin, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|October 11, 2016
Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine modelsAndrew T Lucas, Taylor F White, Allison M Deal, et al.
Pageof 18

Showing results (71-80 of 180) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|May 19, 2011
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patientsNinh M La-Beck, Beth A Zamboni, Alberto Gabizon, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 6, 2007
Effect of moderate aerobic exercise on sympatho-vagal balance in Type 2 diabetic patientsG Zoppini, V Cacciatori, M L Gemma, et al.
Annals of the New York Academy of Sciences|December 13, 1996
Schedule-dependent efficacy of camptothecins in models of human cancerP J Houghton, C F Stewart, W C Zamboni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastomaW C Zamboni, A J Gajjar, R L Heideman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group StudyR L Saylors, C F Stewart, W C Zamboni, et al.
Pharmacotherapy|October 18, 2000
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascitesB J Delauter, R K Ramanathan, M J Egorin, et al.
Antibodies (Basel, Switzerland)|September 24, 2019
Factors Affecting the Pharmacology of Antibody-Drug ConjugatesAndrew T Lucas, Lauren S L Price, Allison N Schorzman, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|August 9, 2019
Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2Christina L Parker, Morgan D McSweeney, Andrew T Lucas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluidW C Zamboni, D I Lüftner, M J Egorin, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|October 11, 2016
Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine modelsAndrew T Lucas, Taylor F White, Allison M Deal, et al.
Pageof 18